Inorganic nitrite and chronic tissue ischaemia: A novel therapeutic modality for peripheral vascular diseases

Cardiovascular Research

Volumn 89, Issue 3, 2011, Pages 533-541

  Pattillo, Christopher B ^a   Bir, Shyamal ^a   Rajaram, Venkat ^a   Kevil, Christopher G ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Angiogenesis; Arteriogenesis; Nitric oxide; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; AMYL NITRITE; ANTITHROMBOCYTIC AGENT; ARGININE; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRITE; PENTOXIFYLLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PRODRUG; PROTEIN KINASE B; PROTEIN KINASE C; SODIUM NITRITE; VASCULAR ENDOTHELIAL CADHERIN; XANTHINE OXIDASE;

ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CYANIDE POISONING; DRUG INDUCED HEADACHE; GENE EXPRESSION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; ISCHEMIA; LIVER ISCHEMIA; LOW DRUG DOSE; METHEMOGLOBINEMIA; NONHUMAN; OXIDATION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; STROKE; SYNCOPE;

ANIMALS; HUMANS; ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; PERIPHERAL VASCULAR DISEASES; PRODRUGS; SODIUM NITRITE;

EID: 79551494651     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq297     Document Type: Article

References (125)

1. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002;53:503-514.
2. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Clin Pharmacol 2006;147 Suppl 1:S193-201.
3. Napoli R, Guardasole V, Zarra E, Matarazzo M, D'Anna C, Sacca F et al. Vascular smooth muscle cell dysfunction in patients with migraine. Neurology 2009;72: 2111-2114.
4. Cooper CE. Nitric oxide and iron proteins. Biochim Biophys Acta 1999;1411: 290-309.
5. Freeman BA, Baker PR, Schopfer FJ, Woodcock SR, Napolitano A, d'Ischia M. Nitro-fatty acid formation and signaling. J Biol Chem 2008;283:15515-15519.
6. Martinez MC, Andriantsitohaina R. Reactive nitrogen species: molecular mechanisms and potential significance in health and disease. Antioxid Redox Signal 2009;11: 669-702.
7. Stamler JS, Hausladen A. Oxidative modifications in nitrosative stress. Nat Struct Biol 1998;5:247-249.
8. Sun J, Steenbergen C, Murphy E. S-nitrosylation NO-related redox signaling to protect against oxidative stress. Antioxid Redox Signal 2006;8:1693-1705.
9. Thomas DD, Miranda KM, Colton CA, Citrin D, Espey MG, Wink DA. Heme proteins and nitric oxide (NO): the neglected, eloquent chemistry in NO redox signaling and regulation. Antioxid Redox Signal 2003;5:307-317.
10. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315-424.
11. Taylor CT, Moncada S. Nitric oxide, cytochrome C oxidase, and the cellular response to hypoxia. Arterioscler Thromb Vasc Biol 2010;30:643-647.
12. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001; 299:818-824.
13. Kone BC, Kuncewicz T, Zhang W, Yu ZY. Protein interactions with nitric oxide synthases: controlling the right time, the right place, and the right amount of nitric oxide. Am J Physiol 2003;285:F178-190.
14. Lancaster JR Jr. A tutorial on the diffusibility and reactivity of free nitric oxide. Nitric Oxide 1997;1:18-30.
15. Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S et al. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med 2008;45:18-31.
16. Laroux FS, Lefer DJ, Kawachi S, Scalia R, Cockrell AS, Gray L et al. Role of nitric oxide in the regulation of acute and chronic inflammation. Antioxid Redox Signal 2000;2:391-396.
17. Lefer DJ. Myocardial protective actions of nitric oxide donors after myocardial ischemia and reperfusion. New Horiz (Baltimore, MD) 1995;3:105-112.
18. Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in the modulation of angiogen-esis. Curr Pharm Des 2003;9:521-530.
19. Cooke JP, Losordo DW. Nitric oxide and angiogenesis. Circulation 2002;105: 2133-2135.
20. Luque Contreras D, Vargas Robles H, Romo E, Rios A, Escalante B. The role of nitric oxide in the post-ischemic revascularization process. Pharmacol Ther 2006;112: 553-563.
21. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997;100:3131-3139.
22. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99: 2625-2634. (Pubitemid 27259809)
23. Kawasaki K, Smith RS Jr., Hsieh CM, Sun J, Chao J, Liao JK. Activation of the phos-phatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol 2003;23:5726-5737.
24. Jones MK, Tsugawa K, Tarnawski AS, Baatar D. Dual actions of nitric oxide on angio-genesis: possible roles of PKC, ERK, and AP-1. Biochem Biophys Res Commun 2004; 318:520-528.
25. Morbidelli L, Pyriochou A, Filippi S, Vasileiadis I, Roussos C, Zhou Z et al. The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability. Am J Physiol Regul Integr Comp Physiol 2008;298:R824-832.
26. Murohara T, Asahara T. Nitric oxide and angiogenesis in cardiovascular disease. Anti-oxid Redox Signal 2002;4:825-831.
27. Duda DG, Fukumura D, Jain RK. Role of eNOS in neovascularization: NO for endo-thelial progenitor cells. Trends Mol Med 2004;10:143-145.
28. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 2001;98:2604-2609.
29. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101:2567-2578.
30. Yu J, deMuinck ED, Zhuang Z, Drinane M, Kauser K, Rubanyi GM et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci USA 2005;102:10999-11004.
31. Jones SP, Girod WG, Palazzo AJ, Granger DN, Grisham MB, Jourd'Heuil D et al. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am J Physiol 1999;276:H1567-1573.
32. Jones SP, Greer JJ, Kakkar AK, Ware PD, Turnage RH, Hicks M et al. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2004;286:H276-282.
33. Boo YC, Kim HJ, Song H, Fulton D, Sessa W, Jo H. Coordinated regulation of endo-thelial nitric oxide synthase activity by phosphorylation and subcellular localization. Free Radic Biol Med 2006;41:144-153.
34. Fulton D, Babbitt R, Zoellner S, Fontana J, Acevedo L, McCabe TJ et al. Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi complex or plasma membrane regulates Akt- vs. calcium-dependent mechanisms for nitric oxide release. J Biol Chem 2004;279:30349-30357.
35. Iwakiri Y, Satoh A, Chatterjee S, Toomre DK, Chalouni CM, Fulton D et al. Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proc Natl Acad Sci USA 2006;103: 19777-19782.
36. Jagnandan D, Sessa WC, Fulton D. Intracellular location regulates calcium-calmodulin-dependent activation of organelle-restricted eNOS. Am J Physiol Cell Physiol 2005;289: C1024-1033.
37. Zhang Q, Church JE, Jagnandan D, Catravas JD, Sessa WC, Fulton D. Functional relevance of Golgi- and plasma membrane-localized endothelial NO synthase in reconstituted endothelial cells. Arterioscler Thromb Vasc Biol 2006;26:1015-1021.
38. Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res 2009;32:1103-1108.
39. Liu VW, Huang PL. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc Res 2008;77:19-29.
40. Furchgott RF. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte PM, ed. Vasodilation: Vascular Smooth Muscle, Peptides, and Endothelium. New York: Raven Press; 1988. p401-414.
41. Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci USA 2001;98:12814-12819.
42. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003;9:1498-1505.
43. Crawford JH, Isbell TS, Huang Z, Shiva S, Chacko BK, Schechter AN et al. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 2006;107:566-574.
44. Gladwin MT. Evidence mounts that nitrite contributes to hypoxic vasodilation in the human circulation. Circulation 2008;117:594-597.
45. Duranski MR, Greer JJ, Dejam A, Jaganmohan S, Hogg N, Langston W et al. Cyto-protective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest 2005;115:1232-1240.
46. Hunter CJ, Dejam A, Blood AB, Shields H, Kim-Shapiro DB, Machado RF et al. Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat Med 2004;10:1122-1127.
47. Dejam A, Hunter CJ, Tremonti C, Pluta RM, Hon YY, Grimes G et al. Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation 2007;116:1821-1831.
48. Doyle MP, Pickering RA, DeWeert TM, Hoekstra JW, Pater D. Kinetics and mechanism of the oxidation of human deoxyhemoglobin by nitrites. J Biol Chem 1981;256: 12393-12398.
49. Patel RP, Hogg N, Kim-Shapiro DB. The potential role of the red blood cell in nitrite-dependent regulation of blood flow. Cardiovasc Res 2011;89:507-515.
50. 2, and NO. J Appl Physiol 2004;97:2284-2302.
51. Huang KT, Huang Z, Kim-Shapiro DB. Nitric oxide red blood cell membrane permeability at high and low oxygen tension. Nitric Oxide 2007;16:209-216.
52. Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol 2006;26:697-705.
53. Alzawahra WF, Talukder MA, Liu X, Samouilov A, Zweier JL. Heme proteins mediate the conversion of nitrite to nitric oxide in the vascular wall. Am J Physiol Heart Circ Physiol 2008;295:H499-508.
54. Zweier JL, Li H, Samouilov A, Liu X. Mechanisms of nitrite reduction to nitric oxide in the heart and vessel wall. Nitric Oxide 2010;22:83-90.
55. Kumar D, Branch BG, Pattillo CB, Hood J, Thoma S, Simpson S et al. Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis. Proc Natl Acad Sci USA 2008;105:7540-7545.
56. Vitturi DA, Teng X, Toledo JC, Matalon S, Lancaster JR Jr., Patel RP. Regulation of nitrite transport in red blood cells by hemoglobin oxygen fractional saturation. Am J Physiol Heart Circ Physiol 2009;296:H1398-1407.
57. Rassaf T, Flogel U, Drexhage C, Hendgen-Cotta U, Kelm M, Schrader J. Nitrite reductase function of deoxymyoglobin: oxygen sensor and regulator of cardiac energetics and function. Circ Res 2007;100:1749-1754.
58. Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, MacArthur PH et al. Deoxymyo-globin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ Res 2007;100:654-661.
59. Garattini E, Mendel R, Romao MJ, Wright R, Terao M. Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J 2003;372:15-32.
60. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci 1988;33:6S-15S.
61. Millar TM, Stevens CR, Benjamin N, Eisenthal R, Harrison R, Blake DR. Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett 1998;427:225-228.
62. Li H, Samouilov A, Liu X, Zweier JL. Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrite reduction. Evaluation of its role in nitric oxide generation in anoxic tissues. J Biol Chem 2001;276:24482-24489.
63. Li H, Samouilov A, Liu X, Zweier JL. Characterization of the effects of oxygen on xanthine oxidase-mediated nitric oxide formation. J Biol Chem 2004;279: 16939-16946.
64. Feelisch M, Fernandez BO, Bryan NS, Garcia-Saura MF, Bauer S, Whitlock DR et al. Tissue processing of nitrite in hypoxia: an intricate interplay of nitric oxide-generating and -scavenging systems. J Biol Chem 2008;283:33927-33934.
65. Webb AJ, Milsom AB, Rathod KS, Chu WL, Qureshi S, Lovell MJ et al. Mechanisms underlying erythrocyte and endothelial nitrite reduction to nitric oxide in hypoxia: role for xanthine oxidoreductase and endothelial nitric oxide synthase. Circ Res 2008;103:957-964.
66. Li H, Kundu TK, Zweier JL. Characterization of the magnitude and mechanism of aldehyde oxidase-mediated nitric oxide production from nitrite. J Biol Chem 2009; 284:33850-33858.
67. Pinder AG, Pittaway E, Morris K, James PE. Nitrite directly vasodilates hypoxic vas-culature via nitric oxide-dependent and -independent pathways. Br J Pharmacol 2009; 157:1523-1530.
68. Grisham MB, Hernandez LA, Granger DN. Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am J Physiol 1986;251:G567-574.
69. Mitsuoka H, Schmid-Schonbein GW. Mechanisms for blockade of in vivo activator production in the ischemic intestine and multi-organ failure. Shock (Augusta, Ga) 2000;14:522-527.
70. Samouilov A, Kuppusamy P, Zweier JL. Evaluation of the magnitude and rate of nitric oxide production from nitrite in biological systems. Arch Biochem Biophys 1998;357: 1-7.
71. Aamand R, Dalsgaard T, Jensen FB, Simonsen U, Roepstorff A, Fago A. Generation of nitric oxide from nitrite by carbonic anhydrase: a possible link between metabolic activity and vasodilation. Am J Physiol Heart Circ Physiol 2009;297:H2068-2074.
72. Basu S, Azarova NA, Font MD, King SB, Hogg N, Gladwin MT et al. Nitrite reductase activity of cytochrome c. J Biol Chem 2008;283:32590-32597.
73. Castello PR, David PS, McClure T, Crook Z, Poyton RO. Mitochondrial cytochrome oxidase produces nitric oxide under hypoxic conditions: implications for oxygen sensing and hypoxic signaling in eukaryotes. Cell Metab 2006;3:277-287.
74. Vanin AF, Bevers LM, Slama-Schwok A, van Faassen EE. Nitric oxide synthase reduces nitrite to NO under anoxia. Cell Mol Life Sci 2007;64:96-103.
75. Dezfulian C, Raat N, Shiva S, Gladwin MT. Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovasc Res 2007;75: 327-338.
76. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC et al. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. Circ Res 1999; 85:950-958.
77. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 1999; 103:1547-1560.
78. Bryan NS, Fernandez BO, Bauer SM, Garcia-Saura MF, Milsom AB, Rassaf T et al. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues. Nat Chem Biol 2005;1:290-297.
79. Shiva S, Sack MN, Greer JJ, Duranski M, Ringwood LA, Burwell L et al. Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med 2007;204:2089-2102.
80. Elrod JW, Calvert JW, Gundewar S, Bryan NS, Lefer DJ. Nitric oxide promotes distant organ protection: evidence for an endocrine role of nitric oxide. Proc Natl Acad Sci USA 2008;105:11430-11435.
81. Venkatesh PK, Pattillo CB, Branch B, Hood J, Thoma S, Illum S et al. Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway. Cardiovasc Res 2010;85:661-670.
82. Lang JD Jr., Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK et al. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest 2007;117:2583-2591.
83. Keltz TN, Innerfield M, Gitler B, Cooper JA. Dipyridamole-induced myocardial ischemia. JAMA 1987;257:1515-1516. (Pubitemid 17075809)
84. Crown N, Mysak T. Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease. Am J Health Syst Pharm 2010 67 728-733.
85. Guideri F, Capecchi PL, Acampa M, Cuomo A, Lazzerini PE, De Giorgi L et al. Oral low-dose dipyridamole protects from intravenous high-dose dipyridamole-induced ischemia. A stress echocardiographic study. Int J Cardiol 2002;83:209-215; discussion 215-206.
86. Hunault CC, van Velzen AG, Sips AJ, Schothorst RC, Meulenbelt J. Bioavailability of sodium nitrite from an aqueous solution in healthy adults. Toxicol Lett 2009;190: 48-53.
87. Baskin SI, Horowitz AM, Nealley EW. The antidotal action of sodium nitrite and sodium thiosulfate against cyanide poisoning. J Clin Pharmacol 1992;32:368-375.
88. Umbreit J. Methemoglobin-it's not just blue: a concise review. Am J Hematol 2007; 82:134-144.
89. Lijinsky W. Significance of in vivo formation of N-nitroso compounds. Oncology 1980; 37:223-226.
90. Mirvish SS. The etiology of gastric cancer. Intragastric nitrosamide formation and other theories. J Natl Cancer Inst 1983;71:629-647.
91. Odashima S. Overview: N-nitroso compounds as carcinogens for experimental animals and man. Oncology 1980;37:282-286.
92. U.S. National Toxicology Program. Toxicology and carcinogenesis studies of sodium nitrite (CAS NO. 7632-00-0) in F344/N rats and B6C3F1 mice (drinking water studies). Natl Toxicol Program Tech Rep Ser 2001;495:7-273.
93. Heller A. Electrochemistry and nitric oxide mass transport in cancer: why ingestion of sodium nitrite could be effective in treating vascularized tumors. Phys Chem Chem Phys 2010;12:9972-9975.
94. Stehouwer CD, Clement D, Davidson C, Diehm C, Elte JW, Lambert M et al. Peripheral arterial disease: a growing problem for the internist. Eur J Intern Med 2009;20: 132-138.
95. Dinh T, Scovell S, Veves A. Peripheral arterial disease and diabetes: a clinical update. Int J Low Extrem Wounds 2009;8:75-81.
96. Huysman E, Mathieu C. Diabetes and peripheral vascular disease. Acta Chir Belg 2009; 109:587-594.
97. Mohler E 3rd, Giri J. Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines. Curr Med Res Opin 2008;24:2509-2522.
98. Welten GM, Schouten O, Chonchol M, Hoeks SE, Bax JJ, Van Domburg RT et al. Prognosis of patients with peripheral arterial disease. J Cardiovasc Surg 2009;50: 109-121.
99. Aronow H, Hiatt WR. The burden of peripheral artery disease and the role of anti-platelet therapy. Postgrad Med 2009;121:123-135.
100. Dobesh PP, Stacy ZA, Persson EL. Pharmacologic therapy for intermittent claudica-tion. Pharmacotherapy 2009;29:526-553.
101. White C. Clinical practice. Intermittent claudication. N Engl J Med 2007;356: 1241-1250.
102. Singh KP, Patel MR, Kandzari DE, Zidar JP. Peripheral arterial disease: an overview of endovascular therapies and contemporary treatment strategies. Rev Cardiovasc Med 2006;7:55-68.
103. Emanueli C, Madeddu P. Therapeutic angiogenesis: translating experimental concepts to medically relevant goals. Vascul Pharmacol 2006;45:334-339.
104. De Haro J, Acin F, Lopez-Quintana A, Florez A, Martinez-Aguilar E, Varela C. Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease. Heart Vessels 2009;24:321-328.
105. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009;105:724-736.
106. Kevil CG, Patel RP. Preserving vessel function during ischemic disease: new possibilities of inorganic nitrite therapy. Expert Rev Cardiovasc Ther 2008;6:1175-1179.
107. Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P et al. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med 2006;40:295-302.
108. Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 2003;35:790-796.
109. Allen JD, Miller EM, Schwark E, Robbins JL, Duscha BD, Annex BH. Plasma nitrite response and arterial reactivity differentiate vascular health and performance. Nitric Oxide 2009;20:231-237.
110. de Haro Miralles J, Martinez-Aguilar E, Florez A, Varela C, Bleda S, Acin F. Nitric oxide: link between endothelial dysfunction and inflammation in patients with peripheral arterial disease of the lower limbs. Interact Cardiovasc Thorac Surg 2009; 9:107-112.
111. Ferlito S, Gallina M, Catassi S, Bisicchia A, Di Salvo MM. Nitrite plasma levels in nor-molipemic and hypercholesterolemic patients with peripheral occlusive arteriopa-thy. Panminerva Med 1999;41:307-309.
112. Mazzone M, Carmeliet P. Drug discovery: a lifeline for suffocating tissues. Nature 2008 453. 1194-1195.
113. Pattillo CB, Fang K, Pardue S, Kevil CG. Genome expression profiling and network analysis of nitrite therapy during chronic ischemia: possible mechanisms and interesting molecules. Nitric Oxide 2010;22:168-179.
114. Vestweber D. VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol 2008;28: 223-232.
115. Wallez Y, Vilgrain I, Huber P. Angiogenesis: the VE-cadherin switch. Trends Cardiovasc Med 2006;16:55-59.
116. Berkes CA, Tapscott SJ. MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol 2005;16:585-595.
117. Yablonka-Reuveni Z, Day K, Vine A, Shefer G. Defining the transcriptional signature of skeletal muscle stem cells. J Anim Sci 2008;86:E207-216.
118. Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 2009;20:295-302.
119. Victor VM, Rocha M, Sola E, Banuls C, Garcia-Malpartida K, Hernandez-Mijares A. Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 2009;15:2988-3002.
120. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-2074.
121. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-4655.
122. Lefer AM, Ma XL. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arterioscler Thromb 1993;13:771-776.
123. De Haro J, Acin F, Lopez-Quintana A, Medina FJ, Martinez-Aguilar E, Florez A et al. Direct association between C-reactive protein serum levels and endothelial dysfunction in patients with claudication. Eur J Vasc Endovasc Surg 2008;35:480-486.
124. De Haro J, Acin F, Medina FJ, Lopez-Quintana A, March JR. Relationship between the plasma concentration of C-reactive protein and severity of peripheral arterial disease. Clin Med 2009;3:1-7.
125. Stokes KY, Dugas TR, Tang Y, Garg H, Guidry E, Bryan NS. Dietary nitrite prevents hypercholesterolemic microvascular inflammation and reverses endothelial dysfunction. Am J Physiol Heart Circ Physiol 2009;296:H1281-1288.